OSI Pharmaceuticals (OSIP) moves up 1.1% as the FDA extends the review date of its lung cancer drug Tarceva 90 days, to April 18.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs